EvlaBio is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a Therapeutic Monoclonal Antibody (mAb) targeting unphysiological FGFR4/FGF23 cardiac overdrive in the setting of chronic kidney disease (CKD).
Member of the Swiss Biotech Association
Member
EvlaBio AG
